ADMA, C-Reactive Protein, and Albuminuria in Untreated Essential Hypertension: A Cross-sectional Study

American Journal of Kidney Diseases

Volumn 55, Issue 6, 2010, Pages 1050-1059

  Tsioufis, Costas ^a   Dimitriadis, Kyriakos ^a   Andrikou, Eirini ^a   Thomopoulos, Costas ^a   Tsiachris, Dimitris ^a   Stefanadi, Elli ^a   Mihas, Costas ^a   Miliou, Antigoni ^a   Papademetriou, Vassilios ^b   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

atherosclerosis; Endothelium; hypertension; inflammation; kidney

Indexed keywords

C REACTIVE PROTEIN; CREATININE; N(G),N(G) DIMETHYLARGININE;

ADULT; AGE DISTRIBUTION; ALBUMINURIA; ARTICLE; CROSS-SECTIONAL STUDY; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PROTEIN INTERACTION; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

ADULT; ALBUMINURIA; ARGININE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CREATININE; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SERUM ALBUMIN;

EID: 77952546772     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2009.11.024     Document Type: Article

References (40)

1. Pedrinelli R., Dell' Omo G., Di Bello V., Pontremolli R., and Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 16 (2002) 79-89
2. Geirstein H., Mann J., Qilong Y., et al., HOPE Study Investigators. Albuminuria and risk of cardiovascular events and heart failure in diabetic and nondiabetic individuals. JAMA 286 (2001) 421-426
3. Tsioufis C., Dimitriadis K., Antoniadis D., Stefanadis C., and Kallikazaros I. Inter-relationships of microalbuminuria with the other surrogates of the atherosclerotic cardiovascular disease in hypertensive subjects. Am J Hypertens 17 (2004) 470-476
4. Tsioufis C., Dimitriadis K., Chatzis D., et al. Relation of microalbuminuria to adiponectin and augmented C-reactive protein levels in men with essential hypertension. Am J Cardiol 96 (2005) 946-951
5. Pedrinelli R., Dell'Omo G., Di Bello V., et al. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 24 (2004) 2414-2419
6. Tsioufis C., Dimitriadis K., Taxiarchou E., et al. Diverse associations of microalbuminuria with C-reactive protein, interleukin-18 and soluble CD 40 ligand in male essential hypertensive subjects. Am J Hypertens 19 (2006) 462-466
7. Engstrom G., Janson L., Berglund G., et al. Inflammation-sensitive plasma proteins and incidence of myocardial infarction in men with low cardiovascular risk. Arterioscler Thromb Vasc Biol 23 (2003) 2247-2251
8. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., and Ridker P.M. C-Reactive protein and the risk of developing hypertension. JAMA 290 22 (2003) 2945-2951
9. Schillaci G., Pirro M., Gemelli F., et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 21 (2003) 1841-1846
10. Chae C., Lee R., Rifai N., and Ridker P. Blood pressure and inflammation in apparently healthy men. Hypertension 38 (2001) 399-403
11. Dzau V.J. Angiotensin and pathophysiology of vascular disease: a unifying hypothesis. Hypertension 37 (2001) 1047-1052
12. Kuwahara F., Kai H., Niiyama H., et al. Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling. Hypertension 41 (2003) 819-823
13. Stuveling E.M., Bakker S.J., Hillege H.L., et al., PREVEND Study Group. C-Reactive protein modifies the relationship between blood pressure and microalbuminuria. Hypertension 43 (2004) 791-796
14. Cooke J.P. Asymmetrical dimethylargine. The uber marker?. Circulation 109 (2004) 1813-1819
15. Zoccali C. Asymmetrical dimethylargine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens 24 (2006) 611-619
16. Boger R.H., and Zoccali C. ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl 4 (2003) 23-28
17. Kielstein J.T., Impraim B., Simmel S., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 109 (2004) 172-179
18. Kielstein J.T., Bode-Boger S.M., Frolich J.C., Ritz E., Haller H., and Fliser D. Asymmetric dimethylarginine, blood pressure and renal perfusion in elderly subjects. Circulation 107 (2003) 1891-1895
19. Zoccali C., Bode-Boger S., Mallamaci F., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
20. Palloshi A., Fragasso G., Piatti P., et al. Effect of oral l-arginine on blood pressure and symptoms and endothelial function in patients with systemic hypertension, positive exercise test and normal coronary arteries. Am J Cardiol 93 (2004) 930-935
21. Takiushi S., Fujii H., Kamide K., et al. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens 17 (2004) 802-808
22. Perticone F., Sciacqua A., Maio R., et al. Asymmetric dimethylarginine, l-arginine and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46 (2005) 518-523
23. Furuki K., Hisashi A., Matsuoka H., et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery. An epidemiological study. Atherosclerosis 191 (2007) 206-210
24. Zoccali C., Mallamaci F., Maas R., et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62 (2002) 339-345
25. Krzyzanowska K., Mittermayer F., Shnawa N., et al. Asymmetrical dimethylarginine is related to renal function, chronic inflammation and macroangiopathy in patients with type 2 diabetes and albuminuria. Diabet Med 24 (2007) 81-86
26. Caglar K., Yilmaz M.I., Sonmez A., et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int 70 (2006) 781-787
27. Tsioufis C., Tsiachris D., Dimitriadis K., et al. Evidence for no global effect of metabolic syndrome per se on early hypertensive sequelae. J Hypertens 26 (2008) 773-779
28. Mancia G., de Backer G., Dominiczak A., et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 6 (2007) 1105-1187
29. Tsioufis C., Stefanadis C., Antoniadis D., et al. Absence of any significant effects of circadian blood pressure variations on carotid artery elastic properties in essential hypertensive subjects. J Hum Hypertens 14 (2000) 813-818
30. National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification and stratification. Am J Kidney Dis 39 2 suppl 1 (2002) S1-S266
31. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricular dimensions by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of the Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
32. Valtonen P., Karppi J., Nyyssonen K., Valkonen V.P., Halonen T., and Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B Analyt Technol Biomd Life Sci 828 (2005) 97-102
33. Surdai A., Nowicki M., Sandmann J., et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33 (1999) 652-658
34. Konukoglu D., Firtine S., and Serin O. The relationship between plasma asymmetrical dimethyl-l-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired and diabetic glucose tolerance. Metabolism 57 1 (2008) 110-115
35. Verdecchia P., Schillaci G., Borgioni C., et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension 32 (1998) 983-988
36. Kielstein J.T., Donnerstag F., Gasper S., et al. ADMA increases arterial stiffness and decreases blood flow in humans. Stroke 37 (2006) 2024-2029
37. Tsioufis C., Dimitriadis K., Kallikazaros I., and Stefanadis C. The emerging role of subclinical inflammation in hypertension-associated early renal dysfunction: focus on microalbuminuria. Hellenic J Cardiol 47 6 (2006) 361-365
38. Krzyzanowska K., Mittermayer F., Wolzt M., and Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 30 (2007) 1834-1839
39. Di Napoli M., and Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first ever ischemic stroke. Stroke 34 (2003) 2922-2929
40. Delles C., Schneider M.P., John S., Gekle M., and Schmieder R.E. Angiotensin converting enzyme inhibition and angiotensin II AT-1 receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 15 (2002) 590-593